Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.870
0.00 (0.00%)
At close: Nov 25, 2025, 4:00 PM EST
1.879
+0.009 (0.49%)
After-hours: Nov 25, 2025, 5:40 PM EST
Caribou Biosciences Employees
Caribou Biosciences had 147 employees as of December 31, 2024. The number of employees decreased by 11 or -6.96% compared to the previous year.
Employees
147
Change (1Y)
-11
Growth (1Y)
-6.96%
Revenue / Employee
$63,231
Profits / Employee
-$1,068,891
Market Cap
174.79M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 147 | -11 | -6.96% |
| Dec 31, 2023 | 158 | 21 | 15.33% |
| Dec 31, 2022 | 137 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRBU News
- 13 days ago - Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 22 days ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
- 22 days ago - Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - GlobeNewsWire
- 22 days ago - Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - GlobeNewsWire
- 23 days ago - Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - GlobeNewsWire
- 3 months ago - Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference - GlobeNewsWire
- 3 months ago - Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire